Human specific sting agonists for the treatment of cancer
Ended Project Grant Awarded Last action
- Award ID
- R41CA275637
- Recipient
-
Stinginn, LLC UEI PJV5A55KF6T5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $330,156
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- Florida, USA
Award details come from USAspending.gov.
Description
- Abstract
- Cellular innate immune sensors, such as sting (stimulator of interferon genes), have evolved to detect microbial infection of the cell (1-3). Sting controls the potent cytosolic DNA-stimulated innate immune pathways and is activated by cyclic dinucleotides (cdns) such as cyclic DI-GMP and cyclic-DI-AMP secreted by intracellular bacteria following infection. Alternatively, sting can be activated by cyclic GMP-AMP (cgamp) generated by a cellular cgamp synthase cgas (MB21D1) after association with aberrant cytosolic dsdna species, which can include microbial DNA or self-DNA leaked from the nucleus (4). Association with cdns enables sting to activate the production of type i interferon (IFN) and pro-inflammatory cytokines, which facilitate adaptive immunity (3). Aside from being critical for the protection against microbial infection, sting signaling has been shown to be essential for facilitating robust anti-tumor immunity. Regulation of the immune system to stimulate anti-tumor cytotoxic t cell responses is proving to be a powerful approach for the effective treatment of a variety of cancers. For example, sting agonists, based on synthetic cdns, have been shown to exert potent anti-tumor properties likely by stimulating apcs and are now being evaluated in phase i trials for the treatment of cancer. However, such cdns are highly labile and do not exert potent activity when given systemically. This has limited their use/evaluation to intratumoral and oral administration. Here, we describe a new generation of novel small sting agonists that activate sting signaling, that appear superior to existing CDN's, for evaluation in anti-tumor therapeutic strategies. The compounds have been generated by stinginn LLC, based in miami, in collaboration with the university of miami school of medicine, FL.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$69,657 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $399,812 |
Quick answers
Who received award R41CA275637?
R41CA275637 was awarded to Stinginn, LLC by National Cancer Institute (National Institutes of Health) on August 1, 2023.
How much is award R41CA275637 worth?
$330,156 has been obligated on R41CA275637.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award